Best Diversified Pharmaceuticals Companies in Germany
The 40 best Diversified Pharmaceuticals companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MorphoSys.
- The Business Research Company
- Data Bridge Market Research
Ranked: Best Diversified Pharmaceuticals companies in Germany
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MorphoSys Developer of antibodies for treating cancer | $770M | 70 mo ago | Acquired | Andreas Pluckthun Co-Founder | 1992 | — | 1,328 patents Therapeutic antibody engineering, formulation, and purification for CD38/CD19 targets | — |
| 2 | Glycotope Developer of Glyco-optimized antibodies and provider of contract research and manufacturing services. | $166M | 130 mo ago | Acquired | Steffen Goletz CEO | 2001 | — | 492 patents Therapeutic antibodies and recombinant production of MUC1 and surfactant protein D. | — |
| 3 | Paion Developing drugs for the hospital-based treatment of central nervous system disorders and… | $48M | 109 mo ago | Public | — | 2000 | TYPO3 CMSApple iCloud MailMicrosoft 365+7 | 20 patents Oral mucosal sedative formulations, synthesis of remimazolam, and stroke plasminogen activators | — |
| 4 | Booster Therapeutics R&D company focused on manufacturing of drugs for multiple therapeutic areas | $15M | 22 mo ago | Seed | Diogo Feleciano Co-Founder | 2020 | — | 5 patents Small-molecule proteasome activators for enhanced targeted protein degradation (TARBODs). | — |
| 5 | Icon Genetics Developing biopharmaceuticals and high-value protein products using green plants as production hosts | $15M | 294 mo ago | Acquired | Yuri Gleba Founder & CEO | 1999 | WordPressMySQLPHP+11 | 322 patents Recombinant protein antigens for vaccines and diagnostics, e.g., norovirus VLPs and syphilis antigens. | — |
| 6 | Refoxy Pharma R&D company manufacturing drugs for multiple therapeutic areas | $10M | 21 mo ago | Seed | — | 2020 | — | — | — |
| 7 | Mologen Vaccines and immunomodulators for the treatment of cancer and infectious diseases | $6M | 101 mo ago | Public | — | 1998 | — | 261 patents Synthetic immunostimulatory oligonucleotides and TLR‑9 agonist DNA constructs for antiviral and cancer immunotherapy. | — |
| 8 | Gruenenthal Group Manufacturer of pain management solutions | — | 41 mo ago | Funding Raised | Christopher Jansen Communications Business Partner Chief Executive Officer And Chief Strategy Officer | 1946 | SitecoreTypeScriptMicrosoft ASP.NET+19 | 5,424 patents Novel analgesic compounds and extended-release formulations for pain management | 1 job opening |
Top 12 Diversified Pharmaceuticals companies in Germany
#1
Seed · Berlin, Berlin · founded 2020 · 3 employees$9.6Mraised▾
R&D company manufacturing drugs for multiple therapeutic areas
- Dec 2024Seed$9.6M
#2
Seed · Berlin, Berlin · founded 2020 · 4 employees$15Mraised▾
R&D company focused on manufacturing of drugs for multiple therapeutic areas
- Oct 2024Seed$15M
#3
Acquired · Planegg, Bavaria · founded 1992 · 732 employees$770.1Mraised▾
Developer of antibodies for treating cancer. It is an integrated biopharma company engaged in the discovery, development, and commercialization of therapeutic antibodies for cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction, and inflammation. Their lead candidate is MOR208 for Diffuse large B cell lymphoma (DLBCL). The company's lead technologies include HuCAL (Human Combinatorial Antibody Library), and Ylanthia (the industry’s largest antibody Fab library which uses novel methods for in vitro generation of specific and human antibodies).
- Oct 2020Post IPO$383.8M
- Jan 2020Post IPO$150M
- Nov 2016Post IPO$123.9M
- Sep 2013Post IPO$112.3M
#4
Acquired · Berlin, Berlin · founded 2001 · 116 employees$166.2Mraised▾
Glycotope develops therapeutics based on glycosylation structures, as well as antibodies against glyco-epitopes on cancer cells. Its leading candidate GlycoBody PankoMab-GE is a proprietary antibody that is currently in phase 2 of clinical trials for ovarian and lung cancer. Other antibodies include EGFR antibody CetuGEX, glyco-optimized cetuximab for head and neck cancer; TrasGEXm, a Glycotope’s HER2 antibody for gastric cancer; and others. It also offers a wide range of analytical, manufacturing and other research services. It also offers immune function assay kits based on flow cytometry procedures.
- Oct 2015Series B$90M
- Mar 2014Series A$76.3M
- 2007Series A—
- 2001Seed—
#5
Public · Aachen, North Rhine Westphalia · founded 2000 · 51 employees$47.7Mraised▾
Paion is specialised in developing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases. Its drug pipeline include Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anaesthetic for anaesthesia (Phase 3) and for procedural sedation (Phase 3); Morphine-6-glucuronide (M6G), a pharmacologically active metabolite of morphine, is suitable for the treatment of post-operative pain (Phase 3); GGF2 (Glial Growth Factor 2) for heart failure (Phase 1). Paion is not actively involved in the development of GGF2 and M6G, but instead benefits from future milestone payments and royalties. GGF2 is developed by Acorda Therapeutics, and M6G is developed by Yichang Humanwell.
- Jul 2017Post IPO$9.2M
- Jun 2016Post IPO$10.6M
- Jul 2014Post IPO$6.7M
- Jul 2014Post IPO$5.4M
#6
Acquired · Halle, Saxony Anhalt · founded 1999 · 25 employees$14.6Mraised▾
Icon Genetics discovers and develops new biopharmaceuticals and high-value protein products using green plants as production hosts. They have developed new generation production platforms and product prototypes for pharmaceutical, animal health and chemical biotech markets. They offer new plant engineering technologies which address speed, yield, precision, expression control and safety of transgene management in plants. Its products include Transgene Operating Systems, a suite of technologies, including nuclear transformation of plants based on translational (promoterless), translation-fusion, and polycistronic vectors, as well as vectors that utilize vector assembly in planta or RNA/protein trans-splicing; plastid transformation that allows construction of transplastomic hosts for high-yield production of specialty proteins in chloroplasts; and pro-viral transfection of plants that provides advantages of fast amplification processes in a plant. The company also offers magnICON system for rapid gene/vector assembly and optimization, as well as for high yield/high throughput expression of genes in planta; lexICON system allows DNA 'bar-coding' of genetically modified plants; and ru
- Mar 2002Series A$2.6M
- Jan 2000Series A$12M
#7
Public · Berlin, Berlin · founded 1998 · 38 employees$6.2Mraised▾
Mologen is a biotechnology company working on the research and clinical development of immunotherapy in the fields of oncology and infectious diseases. Its technology includes dSLIM® and EnanDIM® (Enantiomeric, DNA-based) which influences immune system; MIDGE® vector system which genetically modifies tumor cells; and Allogeneic tumor cell bank for cell-based cancer therapy. Its lead cancer product Lefitolimod (MGN1703) is in clinical trials for colorectal, lung and other solid tumors. It also has other pipeline products for Renal cancer, Melanoma and infectious diseases like HIV, Leishmaniasis.
- Mar 2018Post IPO$6.2M
#8
Funding Raised · Aachen, North Rhine Westphalia · founded 1946 · 10 employees—raised▾
Manufacturer of pain management solutions. The company focuses on developing medicines and solutions for patients with severe diseases and high unmet medical needs. It is dedicated to improving patients’ quality of life through innovative medicines and responsible use of opioids. The company strives to provide effective medication to patients worldwide and collaborates with stakeholders from the pain management field.
#9
Funding Raised · Ingelheim am Rhein, Rhineland Palatinate · founded 1885 · 51015 employees—raised▾
Provider of generic drugs and clinical research services
#10
Funding Raised · Hesse · founded 1946 · 943 employees—raised▾
Biotest is a specialist supplier of plasma proteins and biotherapeutic drugs used to treat diseases of the immune system or the haematopoietic system. The value chain of the medium-sized company, which was founded in 1946 as a family business, ranges from pre-clinical and clinical development to worldwide marketing. Biotest specialises primarily in the fields of clinical immunology, haematology as well as intensive care and emergency medicine. As the world market leader in hyperimmunoglobulins and the only manufacturer of IgM-enriched immunoglobulins, Biotest sees itself as an expert for innovative products for the prevention and therapy of life-threatening and rare infections.
#11
Acquired · Dreieich, State of Hessen · founded 1946 · 1119 employees—raised▾
Biotest is a manufacturer and provider of plasma proteins and biological drugs. The company's product pipeline includes immunoglobulins, coagulation factors and albumins used for clinical immunology, haematology and intensive medicine. It is also developing monoclonal antibody (mAbs) used for the treatment of cancer and systemic lupus erythematosus.
#12
Series C · Eschborn, State of Hessen · founded 2011 · 141 employees—raised▾
AI-based life Sciences company that provides solutions for discovering and developing safer and more successful medicines by leveraging its proprietary ontosight AI search platform.
- Apr 2019Series C—
- Dec 2016Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.